Fig. 2: Overall survival in the second-line subgroup. | npj Breast Cancer

Fig. 2: Overall survival in the second-line subgroup.

From: Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

Fig. 2

Assessed in the brain metastasis-negative population. Second-line patients were defined as those who received one line of therapy in the metastatic setting and recurred ≤12 months after (neo)adjuvant chemotherapy, prior to study enrollment. HR hazard ratio, (neo)adjuvant neoadjuvant or adjuvant, OS overall survival, SG sacituzumab govitecan, TPC treatment of physician’s choice.

Back to article page